DESCIN BV

Their core work

DESCIN BV is a Dutch biotech SME working at the interface of cardiovascular disease and molecular medicine. Their core work involves understanding how innate immune cells contribute to conditions like atherosclerosis and ischemic heart failure — specifically through epigenetic reprogramming and the concept of "trained immunity," where immune cells retain a memory of past stimuli. Beyond basic mechanisms, they have moved into therapeutic strategy, working with RNA-based tools (microRNA, lncRNA, antisense oligonucleotides) and nanomedicine delivery systems to intervene in heart disease. In EU consortia, they function as a specialist scientific contributor bringing cardiovascular biology expertise to larger collaborative programs.

What they specialise in

How they've shifted over time

In their first H2020 project (REPROGRAM, 2016–2019), DESCIN concentrated on the biological mechanisms upstream of cardiovascular disease — how epigenetic changes in innate immune cells drive atherosclerosis and chronic inflammation, particularly through the trained immunity concept. From 2019 onward, with TRAIN-HEART, their keywords shift decisively toward molecular therapeutic tools: microRNA, lncRNA, antisense oligonucleotides, and nanomedicine — all technologies aimed at clinical intervention rather than mechanistic understanding alone. This represents a clear trajectory from basic immunological research toward translational RNA-based cardiovascular therapy.

DESCIN is moving from studying disease mechanisms toward contributing to RNA-based therapeutic strategies for heart disease, positioning them as relevant partners for cardiovascular drug discovery programs.

How they like to work

DESCIN has never coordinated an H2020 project — both participations are as consortium member or third-party partner, which points to a specialist contributor model rather than a project-driving one. Despite only two projects, they have connected with 25 distinct partners across 12 countries, suggesting they integrate into substantial multi-partner consortia rather than small bilateral collaborations. Working with them likely means engaging a focused scientific expert who fits into a defined work-package role rather than expecting project management or strategic leadership.

DESCIN has built a surprisingly broad network for a two-project SME — 25 partners across 12 countries, almost certainly anchored in the large international consortia typical of Health-pillar RIA and MSCA-ITN projects. Their geographic spread points to integration with established European cardiovascular research networks.

What sets them apart

DESCIN is unusual as a private SME operating at a relatively early research stage — their work on trained immunity and epigenetic modulation sits closer to academic science than typical biotech product development, yet they bring commercial discipline to these consortia. Their combination of immunological expertise (innate immunity, epigenetics) and emerging capability in RNA therapeutics and nanomedicine is a rare profile for a company of this size. For consortium builders, they offer the credibility of a private-sector participant without requiring the project to be industry-ready — valuable in Health-pillar projects that need SME involvement but are still at TRL 2–4.

Highlights from their portfolio

• REPROGRAM
  Their primary funded project (EUR 221,500) and the foundation of their H2020 profile, targeting the epigenetic mechanisms linking trained immunity to atherosclerosis — a research area of growing pharmaceutical interest.
• TRAIN-HEART
  An MSCA-ITN training network where DESCIN participated as a third party, signaling their ability to contribute to researcher training programs in cardiovascular RNA therapeutics — a role distinct from typical research participation.